1. Home
  2. Nation
  3. WHO on Covaxin approval: Cannot cut corners, expecting more info from Bharat Biotech

WHO on Covaxin approval: Cannot cut corners, expecting more info from Bharat Biotech

By Priyanka Verma 
Updated Date
WHO on Covaxin approval: Cannot cut corners, expecting more info from Bharat Biotech

The World Health Organization (WHO) on Monday said that it was aware that many people were waiting for its recommendation for Bharat Biotech’s Covid vaccine Covaxin to be included in the Emergency Use Listing, but it cannot cut corners. “Before recommending a product for emergency use, we must evaluate it thoroughly to make sure it is safe and effective,” it said.

Also Read :- WHO urges these nations to be vigilant as new Covid-19 variant Omicron surfaces

Bharat Biotech has been submitting data to WHO on a rolling basis and WHO experts have reviewed these data. “WHO is expecting one additional piece of information from the company today,” the UN health agency said.

It further said that the timeframe for the Emergency Use Listing procedure is dependent on how quickly a company producing the vaccine is able to provide the data required for WHO to evaluate the vaccine’s quality, safety, efficacy and its suitability for low and middle-income countries.

“We are aware that many people are waiting for WHO’s recommendation for (Bharat Biotech’s) Covaxin to be included in the #COVID19 Emergency Use Listing, but we cannot cut corners,” WHO said on Twitter.

Also Read :- Covaxin meets WHO criteria for Delta, shows Lancet study: Bharat Biotech

Bharat Biotech did not immediately respond to a Reuters request for comment.

Covaxin is one of the three approved vaccines that have been used in India for the country’s vaccination drive for adults. Around 30% of about 944 million eligible adults have been fully vaccinated so far, which includes the administration of more than 112 million doses of Covaxin.

“Bharat Biotech … has been submitting data to WHO on a rolling basis and WHO experts have reviewed these data. WHO is expecting one additional piece of information from the company today,” the global health agency said on Twitter.

WHO’s chief scientist Soumya Swaminathan said on Sunday the agency’s technical advisory group will meet on Oct. 26 to consider the listing for Covaxin.

Also Read :- India's Covaxin only 50% effective against symptomatic Covid cases: Lancet study
Further reading:
For the latest news and reviews, follow us on Facebook and Twitter ...